Challenges in the treatment of Alzheimer’s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors

References

• Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–56.
   PubMed Web of Science ®Google Scholar
• Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15:455–532.
   PubMed Web of Science ®Google Scholar
• Godyn J, Jonczyk J, Panek D, et al. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep. 2016;68:127–138.
   PubMed Web of Science ®Google Scholar
• Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2016;12:110–120.
   PubMed Web of Science ®Google Scholar
• Dubios B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323.
   PubMed Web of Science ®Google Scholar
• Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Solfrizzi V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert Rev Neurother. 2018;18:847–857.
   PubMed Web of Science ®Google Scholar
• Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 2016;12:719–732.
   PubMed Web of Science ®Google Scholar
• Strooper BD, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016;164:603–615.
   PubMed Web of Science ®Google Scholar
• Zhang TT, Li W, Meng G, et al. Strategies for transporting nanoparticles across the blood-brain barrier. Biomater Sci. 2016;4:219–229.
   PubMed Web of Science ®Google Scholar
• Liu Y, An S, Li J, et al. Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer’s disease mice. Biomaterials. 2016;80:33–45.
   PubMed Web of Science ®Google Scholar
• Chen ZL, Huang M, Wang XR, et al. Transferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrier. Nanomed Nanotech Biol Med. 2016;12:421–430.
   PubMed Web of Science ®Google Scholar
• Vedagiri A, Thangarajan S. Mitigating effect of chrysin loaded solid lipid nanoparticles against amyloid β25–35 induced oxidative stress in rat hippocampal region: an efficient formulation approach for Alzheimer’s disease. Neuropeptides. 2016;58:111–125.
   PubMed Web of Science ®Google Scholar
• Loureiro JA, Gomes B, Fricker G, et al. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment. Colloids Surf B. 2016;145:8–13.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lin CY, Li JS, et al. Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer’s disease treatment. Int J Nanomed. 2017;12:1757–1774.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Tsao CW. Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin. Int J Nanomed. 2017;12:2857–2869.
   PubMed Web of Science ®Google Scholar
• Tamaru M, Akita H, Nakatani T, et al. Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain. Int J Nanomed. 2014;9:4267–4276.
   PubMed Web of Science ®Google Scholar
• Tamaru M, Akita H, Kajimoto K, et al. An apolipoprotein E modified liposomal nanoparticle: ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells. Int J Pharm. 2014;465:77–82.
   PubMed Web of Science ®Google Scholar
• Poirier J, Miron J, Picard C, et al. Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer’s disease. Neurobiol Aging. 2014;35:S3–10.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lin CY. Targeting delivery of liposomes with conjugated p-aminophenyl-α-d-manno-pyranoside and apolipoprotein E for inhibiting neuronal degeneration insulted with β-amyloid peptide. J Drug Target. 2015;23:147–158.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lee YJ. Rescuing cholinergic neurons from apoptotic degeneration by targeting of serotonin modulator- and apolipoprotein E-conjugated liposomes to hippocampus. Int J Nanomed. 2016;11:6809–6824.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Rajesh R. A critical overview of therapeutic strategy and advancement for Alzheimer’s disease treatment. J Taiwan Inst Chem Eng. 2016;77:92–105.
   Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–333.
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–321.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873–2884.
   PubMed Web of Science ®Google Scholar
• Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1430–1440.
   PubMed Web of Science ®Google Scholar
• Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer’s disease. J Alzheimers Dis. 2015;45:75–88.
   PubMed Web of Science ®Google Scholar
• Davtyan H, Ghochikyan A, Petrushina I, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial. J Neurosci. 2013;33:4923–4934.
   PubMed Web of Science ®Google Scholar
• Lee ST, Chu K, Park JE, et al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer’s disease models. J Neurochem. 2012;120:115–124.
   PubMed Web of Science ®Google Scholar
• Burstein AH, Dunn I, Soeder T, et al. Azeliragon phase 2b survival analysis supports beneficial effects on delaying time to cognitive deterioration in patients with mild Alzheimer’s disease. Alzheimers Dement. 2016;12:352.
   Google Scholar
• Timmers M, Broeck BV, Ramael S, et al. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement. 2016;2:202–212.
   Google Scholar
• Sakamoto K, Matsuki S, Matsuguma K, et al. BACE1 Inhibitor lanabecestat (AZD3293) in a phase 1 study of healthy Japanese subjects: pharmacokinetics and effects on plasma and cerebrospinal fluid Aβ peptides. J Clin Pharmacol. 2017;57:1460–1471.
   PubMed Web of Science ®Google Scholar
• Hawkes N. Merck ends trial of potential Alzheimer’s drug verubecestat. Bmj. 2017;356:j845.
   PubMed Web of Science ®Google Scholar
• Lai RYK, Darpo B, Dayal S, et al. Elenbecestat, a novel oral BACE inhibitor, has no clinically meaningful effect on QTC interval up to a supratherapeutic dose of 200 mg. Alzheimers Dement. 2017;13:250–251.
   Google Scholar
• Ulfer M, Rouzade-Dominguez ML, Huledal G, et al. Results from a 3-month study in healthy subjects aged 60 years with the BACE inhibitor CNP520. Alzheimers Dement. 2017;7:256.
   Google Scholar
• Sun X, Cheng WD, Wang YD. β-amyloid: the key peptide in the pathogenesis of Alzheimer’s disease. Front Pharmacol. 2015;6:1–9.
   PubMed Web of Science ®Google Scholar
• Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76:185–205.
   PubMed Web of Science ®Google Scholar
• Sevalle J, Amoyel A, Robert P, et al. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem. 2009;109:248–256.
   PubMed Web of Science ®Google Scholar
• Schonherr C, Bein J, Isbert S, et al. Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site. ‎Mol Neurodegener. 2016;11:1–16.
   PubMed Web of Science ®Google Scholar
• Leissring MA, Lu A, Condron MM, et al. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J Biol Chem. 2003;278:37314–37320.
   PubMed Web of Science ®Google Scholar
• Liao MC, Ahmed M, Smith SO, et al. Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem. 2009;284:28917–28925.
   PubMed Web of Science ®Google Scholar
• Hu J, Igarashi A, Kamata M, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 2001;276:47863–47868.
   PubMed Web of Science ®Google Scholar
• Nostrand WEV, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry. 1999;38:11570–11576.
   PubMed Web of Science ®Google Scholar
• Baranello RJ, Bharani KL, Padmaraju V, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s disease. Curr Alzheimer Res. 2015;12:32–46.
   PubMed Web of Science ®Google Scholar
• Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci. 2014;124:307–321.
   PubMed Web of Science ®Google Scholar
• Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer’s disease. Biochem Pharmacol. 2014;88:594–604.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160:1061–1071.
   PubMed Web of Science ®Google Scholar
• Yeh FL, Wang Y, Tom I, et al. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;16:328–340.
   Web of Science ®Google Scholar
• Griciu A, Serrano-Pozo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631–643.
   PubMed Web of Science ®Google Scholar
• Killick R, Ribe EM, Al-Shawi R, et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry. 2014;19:88–98.
   PubMed Web of Science ®Google Scholar
• Hamelin L, Lagarde J, Dorothee G, et al. Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139:1252–1264.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Sagare AP, Ma Q, et al. Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nature Neurosci. 2015;18:978–987.
   PubMed Web of Science ®Google Scholar
• Hane F, Leonenko Z. Effect of metals on kinetic pathways of amyloid-β aggregation. Biomolecules. 2014;4:101–116.
   PubMedGoogle Scholar
• Faller P, Hureau C, Penna GL. Metal ions and intrinsically disordered proteins and peptides: from Cu/Zn amyloid-β to general principles. Acc Chem Res. 2014;47:2252–2259.
   PubMed Web of Science ®Google Scholar
• Notarachille G, Arnesano F, Calo V, et al. Heavy metals toxicity: effect of cadmium ions on amyloid beta protein 1–42. Possible implications for Alzheimer’s disease. Biometals. 2014;27:371–388.
   PubMed Web of Science ®Google Scholar
• Pimplikar SW, Nixon RA, Robakis NK, et al. Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J Neurosci. 2010;30:14946–14954.
   PubMed Web of Science ®Google Scholar
• Kumar S, Wirths O, Stuber K, et al. Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathol. 2016;131:525–537.
   PubMed Web of Science ®Google Scholar
• Umeda T, Tomiyama T, Sakama N, et al. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res. 2011;89:1031–1042.
   PubMed Web of Science ®Google Scholar
• Cheng B, Gong H, Xiao H, et al. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. Biochim Biophys Acta Gen Subj. 2013;1830:4860–4871.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Osswald HL. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev. 2014;43:6765–6813.
   PubMed Web of Science ®Google Scholar
• Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014;13:319–329.
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang X, Zhang Y, et al. Alzheimer’s β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid. J Neurosci. 2012;32:11390–11395.
   PubMed Web of Science ®Google Scholar
• Devi L, Ohno M. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2012;37:434–444.
   PubMed Web of Science ®Google Scholar
• Chen CH, Zhou W, Liu S, et al. Increased NF-kB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2012;15:77–90.
   PubMed Web of Science ®Google Scholar
• Marwarh G, Raza S, Prasanthi JRP, et al. Gadd153 and NF-kB crosstalk regulates 27-hydroxycholesterol-induced increase in BACE1 and β-amyloid production in human neuroblastoma SH-SY5Y cells. PLOS One. 2013;8:e70773.
   PubMed Web of Science ®Google Scholar
• Prabhu Y, Burgos PV, Schindler C, et al. Adaptor protein 2-mediated endocytosis of the β-secretase BACE1 is dispensable for amyloid precursor protein processing. Mol Biol Cell. 2012;23:2339–2351.
   PubMed Web of Science ®Google Scholar
• Cumming JN, Smith EM, Wang L, et al. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Bioorg Med Chem Lett. 2012;22:2444–2449.
   PubMed Web of Science ®Google Scholar
• Stamford AW, Wu Y, Scott JD, et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Aβ reduction. ACS Med Chem Lett. 2012;3:897–902.
   PubMed Web of Science ®Google Scholar
• Hilpert H, Guba W, Woltering TJ, et al. β-secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer’s disease. J Med Chem. 2013;56:3980–3995.
   PubMed Web of Science ®Google Scholar
• Yonezawa S, Yamakawa H, Muto C, et al. Conformational restriction approach to BACE1 inhibitors II: SAR study of the isocytosine derivatives fixed with a cis-cyclopropane ring. Bioorg Med Chem Lett. 2013;23:2912–2915.
   PubMed Web of Science ®Google Scholar
• Edraki N, Firuzi O, Foroumadi A, et al. Phenylimino-2H-chromen-3-carboxamide derivatives as novel small molecule inhibitors of β-secretase (BACE1). Bioorg Med Chem Lett. 2013;21:2396–2412.
   Web of Science ®Google Scholar
• Hettich MM, Matthes F, Ryan DP, et al. The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex. PLOS One. 2014;9:e102420.
   PubMed Web of Science ®Google Scholar
• Thomas AA, Hunt KW, Volgraf M, et al. Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous system. J Med Chem. 2014;57:878–902.
   PubMed Web of Science ®Google Scholar
• Dineen TA, Chen K, Cheng AC, et al. Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718). J Med Chem. 2014;57:9811–9831.
   PubMed Web of Science ®Google Scholar
• Epstein O, Bryan MC, Cheng AC, et al. Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2014;57:9796–97810.
   PubMed Web of Science ®Google Scholar
• Lu X, Deng Y, Yu D, et al. Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer’s disease. PLOS One. 2014;9:e103067.
   PubMed Web of Science ®Google Scholar
• Marwarha G, Raza S, Meiers C, et al. Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim Biophys Acta. 2014;1842:1587–1595.
   PubMed Web of Science ®Google Scholar
• Adwan L, Subaiea GM, Zawia NH. Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer’s disease related biomarkers. Neuropharmacology. 2014;79:596–602.
   PubMed Web of Science ®Google Scholar
• Wang Q, Xiao B, Cui S, et al. Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. Dis Models Mech. 2014;7:1385–1395.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen S, Liu Y, et al. All-trans-retinoic acid reduces BACE1 expression under inflammatory conditions via modulation of nuclear factor κB (NFκB) signaling. J Biol Chem. 2015;37:22532–22542.
   Web of Science ®Google Scholar
• Zheng N, Yuan P, Li C, et al. Luteolin reduces BACE1 expression through NF-κB and estrogen receptor mediated pathways in HEK293 and SH-SY5Y cells. J Alzheimers Dis. 2015;45:659–671.
   PubMed Web of Science ®Google Scholar
• Filser S, Ovsepian SV, Masana M, et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry. 2015;77:729–739.
   PubMed Web of Science ®Google Scholar
• Orejana L, Barros-Minones L, Jordan J, et al. Sildenafil decreases BACE1 and cathepsin B levels and reduces APP amyloidogenic processing in the SAMP8 mouse. J Gerontol A Biol Sci Med Sci. 2015;70:675–685.
   PubMed Web of Science ®Google Scholar
• Qi C, Bao J, Wang J, et al. Asperterpenes A and B, two unprecedented meroterpenoids from Aspergillus terreus with BACE1 inhibitory activities. Chem Sci. 2016;7:6563–6572.
   PubMed Web of Science ®Google Scholar
• Zhang JS, Zhou SF, Wang Q, et al. Gastrodin suppresses BACE1 expression under oxidative stress condition via inhibition of the PKR/eIF2a pathway in Alzheimer’s disease. Neuroscience. 2016;325:1–9.
   PubMed Web of Science ®Google Scholar
• Chon SH, Yang EJ, Lee T, et al. β-Secretase (BACE1) inhibitory and neuroprotective effects of p-terphenyls from polyozellus multiplex. Food Funct. 2016;7:3834–3842.
   PubMed Web of Science ®Google Scholar
• Butler CR, Ogilvie K, Martinez-Alsina L, et al. Aminomethyl-derived beta secretase (BACE1) inhibitors: engaging Gly230 without an anilide functionality. J Med Chem. 2017;60:386–402.
   PubMed Web of Science ®Google Scholar
• Fang M, Wang J, Zhang X, et al. The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer’s disease. Toxicol Lett. 2012;209:94–105.
   PubMed Web of Science ®Google Scholar
• Zhu HC, Wang LM, Wang M, et al. MicroRNA-195 downregulates Alzheimer’s disease amyloid-β production by targeting BACE1. Brain Res Bull. 2012;88:596–601.
   PubMed Web of Science ®Google Scholar
• Liu L, Martin R, Chan C. Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. Neurobiol Aging. 2013;34:540–550.
   PubMed Web of Science ®Google Scholar
• Yun SM, Cho SJ, Song JC, et al. SUMO1 modulates Aβ generation via BACE1 accumulation. Neurobiol Aging. 2013;34:650–662.
   PubMed Web of Science ®Google Scholar
• Chlebek J, Simone AD, Hostalkova A, et al. Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer’s disease targets. Fitoterapia. 2016;109:241–247.
   PubMed Web of Science ®Google Scholar
• Youn K, Jun M. In vitro BACE1 inhibitory activity of geraniin and corilagin from geranium thunbergii. Planta Med. 2013;79:1038–1042.
   PubMed Web of Science ®Google Scholar
• Youn K, Jeong WS, Jun M. β-secretase (BACE1) inhibitory property of loganin isolated from Corni fructus. Nat Prod Res. 2013;27:1471–1474.
   PubMed Web of Science ®Google Scholar
• Veerappan K, Natarajan S, Subramaniyam S, et al. Identification of BACE1 inhibitors from Panax ginseng saponins-an Insilco approach. Comput Biol Med. 2013;43:1037–1044.
   PubMed Web of Science ®Google Scholar
• Yu F, Zhang Y, Chuang DM. Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma. 2012;29:2432–2451.
   Web of Science ®Google Scholar
• Li S, Liu Z, Ji F, et al. Delivery of quantum dot-siRNA nanoplexes in SK-N-SH cells for BACE1 gene silencing and intracellular imaging. Mol Ther Nucleic Acids. 2012;1:e20.
   PubMedGoogle Scholar
• Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Sci Transl Med. 2016;8:363ra150.
   PubMed Web of Science ®Google Scholar
• Woltering TJ, Wostl W, Hilpert H, et al. BACE1 inhibitors: a head group scan on a series of amides. Bioorg Med Chem Lett. 2013;23:4239–4243.
   PubMed Web of Science ®Google Scholar
• Jeppsson F, Eketjall S, Janson J, et al. Discovery of AZD3839, a potent and selective bace1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012;287:41245–41257.
   PubMed Web of Science ®Google Scholar
• May PC, Willis BA, Lowe SL, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35:1199–1210.
   PubMed Web of Science ®Google Scholar
• Eketjall S, Janson J, Kaspersson K, et al. AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. J Alzheimers Dis. 2016;50:1109–1123.
   PubMed Web of Science ®Google Scholar
• Golde TE, Koo EH, Felsensteinv KM, et al. γ-Secretase inhibitors and modulators. Biochim Biophys Acta Biomembr. 2013;1828:2898–2907.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Yarimizu J, Saita K, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012;32:2037–2050.
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–350.
   PubMed Web of Science ®Google Scholar
• Pozdnyakov N, Murrey HE, Crump CJ, et al. γ-secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem. 2013;288:9710–9720.
   PubMed Web of Science ®Google Scholar
• Bischoff F, Berthelot D, Cleyn MD, et al. Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators. J Med Chem. 2012;55:9089–9106.
   PubMed Web of Science ®Google Scholar
• Rogers K, Felsenstein KM, Hrdlicka L, et al. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. ‎Mol Neurodegener. 2012;7:61.
   PubMed Web of Science ®Google Scholar
• Findeis MA, Schroeder F, McKee TD, et al. Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci. 2012;3:941–951.
   PubMed Web of Science ®Google Scholar
• Jung JI, Ladd TB, Kukar T, et al. Steroids as γ-secretase modulators. Faseb J. 2013;27:3775–3785.
   PubMed Web of Science ®Google Scholar
• Yu Y, Logovinsky V, Schuck E, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol. 2014;54:528–536.
   PubMed Web of Science ®Google Scholar
• Loureiro RM, Dumin JA, McKee TD, et al. Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models. Alzheimers Res Ther. 2013;5:19.
   PubMed Web of Science ®Google Scholar
• Chena JJ, Qiana W, Biswasa K, et al. Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2013;23:6447–6454.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Akashiba H, Saita K, et al. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer’s disease, in rodents and nonhuman primates. Neuropharmacology. 2014;79:412–419.
   PubMed Web of Science ®Google Scholar
• Pettersson M, Johnson DS, Subramanyam C, et al. Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators. J Med Chem. 2014;57:1046–1062.
   PubMed Web of Science ®Google Scholar
• Soares HD, Gasior M, Toyn JH, et al. The γ-secretase modulator, BMS-932481, modulates Aβ peptides in the plasma and cerebrospinal fluid of healthy volunteers. J Pharmacol Exp Ther. 2016;358:138–150.
   PubMed Web of Science ®Google Scholar
• Blain JF, Bursavich MG, Freeman EA, et al. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer’s disease. Alzheimers Res Ther. 2016;8:34.
   PubMed Web of Science ®Google Scholar
• Pettersson M, Johnson DS, Humphrey JM, et al. Design of pyridopyrazine-1,6-dione γ-secretase modulators that align potency, MDR efflux ratio, and metabolic stability. ACS Med Chem Lett. 2015;6:596–601.
   PubMed Web of Science ®Google Scholar
• Takai T, Hoashi Y, Tomata Y, et al. Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators. Bioorg Med Chem Lett. 2015;25:4245–4249.
   PubMed Web of Science ®Google Scholar
• Pohland M, Hagl S, Pellowska M, et al. MH84: a novel γ-secretase modulator/PPARγ agonist- improves mitochondrial dysfunction in a cellular model of Alzheimer’s disease. Neurochem Res. 2016;14:231–232.
   Web of Science ®Google Scholar
• Toyn JH, Boy KM, Raybon J, et al. Robust translation of γ-secretase modulator pharmacology across preclinical species and human subjects. J Pharmacol Exp Ther. 2016;358:125–137.
   PubMed Web of Science ®Google Scholar
• Takai T, Koike T, Honda E, et al. Design and synthesis of piperazine derivatives as a novel class of γ-secretase modulators that selectively lower Aβ42 production. Bioorg Med Chem. 2015;23:1923–1934.
   PubMed Web of Science ®Google Scholar
• Jung JI, Price AR, Ladd TB, et al. Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator. ‎Mol Neurodegener. 2015;10:29.
   PubMed Web of Science ®Google Scholar
• Scannevin RH, Chollate S, Brennan MS, et al. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer’s disease. Neuropharmacology. 2016;103:57–68.
   PubMed Web of Science ®Google Scholar
• Rynearson KD, Buckle RN, Barnes KD, et al. Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme. Bioorg Med Chem Lett. 2016;26:3928–3937.
   PubMed Web of Science ®Google Scholar
• Pettersson M, Johnson DS, Rankic DA, et al. Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy. Med Chem Commun. 2017;8:730–743.
   Web of Science ®Google Scholar
• Takai T, Koike T, Nakamura M, et al. Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators (Part 2). Bioorg Med Chem. 2016;24:3192–31206.
   PubMed Web of Science ®Google Scholar
• Shi J, Zuev D, Xu L, et al. Design and optimization of tricyclic gamma-secretase modulators. Bioorg Med Chem Lett. 2016;26:1498–1502.
   PubMed Web of Science ®Google Scholar
• Kounnasa MZ, Lane-Donovanb C, Nowakowskic DW, et al. NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ42, in cerebrospinal fluid while preventing Alzheimer’s disease cognitive decline in rodents. Alzheimers Dement. 2017;3:65–73.
   Google Scholar
• Rammes G, Gravius A, Ruitenberg M, et al. MRZ-99030 – a novel modulator of Aβ aggregation: II – reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. Neuropharmacology. 2015;92:170–182.
   PubMed Web of Science ®Google Scholar
• Borgegard T, Jureus A, Olsson F, et al. First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms. J Biol Chem. 2012;287:11810–11819.
   PubMed Web of Science ®Google Scholar
• Crump CJ, Johnson DS, Li YM. Development and mechanism of γ-secretase modulators for Alzheimer’s disease. Biochemistry. 2013;52:3197–3216.
   PubMed Web of Science ®Google Scholar
• Jumpertz T, Rennhack A, Ness J, et al. Presenilin is the molecular target of acidic γ-secretase modulators in living cells. PLOS One. 2012;7:e30484.
   PubMed Web of Science ®Google Scholar
• Takeo K, Tanimura S, Shinoda T, et al. Allosteric regulation of γ-secretase activity by a phenylimidazole-type γ-secretase modulator. Proc Natl Acad Sci USA. 2014;111:10544–10549.
   PubMed Web of Science ®Google Scholar
• Wagner SL, Zhang C, Cheng S, et al. Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. Biochemistry. 2014;53:702–713.
   PubMed Web of Science ®Google Scholar
• Hubbs JL, Fuller NO, Austin WF, et al. Optimization of a natural product-based class of γ-secretase modulators. J Med Chem. 2012;55:9270–9282.
   PubMed Web of Science ®Google Scholar
• Hayashi I, Takatori S, Urano Y, et al. Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene. 2012;31:787–798.
   PubMed Web of Science ®Google Scholar
• Ferreira ST, Lourenco MV, Oliveira MM, et al. Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease. Front Cell Neurosci. 2015;9:191.
   PubMed Web of Science ®Google Scholar
• Esparza TJ, Zhao H, Cirrito JR, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73:104–119.
   PubMed Web of Science ®Google Scholar
• Takeda S, Hashimoto T, Roe AD, et al. Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer’s disease. Faseb J. 2013;27:3239–3248.
   PubMed Web of Science ®Google Scholar
• Parajuli B, Sonobe Y, Horiuchi H, et al. Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer’s disease. Cell Death Dis. 2013;4:e975.
   PubMed Web of Science ®Google Scholar
• Mohamed LA, Qosa H, Kaddoumi A. Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats. ACS Chem Neurosci. 2015;6:725–736.
   PubMed Web of Science ®Google Scholar
• Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122:1377–1392.
   PubMed Web of Science ®Google Scholar
• Um JW, Nygaard HB, Heiss JK, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15:1227–1235.
   PubMed Web of Science ®Google Scholar
• Frenkel D, Wilkinson K, Zhao L, et al. Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression. Nat Commun. 2013;4:2030.
   PubMed Web of Science ®Google Scholar
• Yuyama K, Sun H, Mitsutake S, et al. Sphingolipid-modulated exosome secretion promotes clearance of amyloid-β by microglia. J Biol Chem. 2012;287:10977–10989.
   PubMed Web of Science ®Google Scholar
• Michaud JP, Bellavance MA, Prefontaine P, et al. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep. 2013;5:646–653.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang B, O’Callaghan P, et al. Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol. 2012;124:465–478.
   PubMed Web of Science ®Google Scholar
• Gontier G, George C, Chaker Z, et al. Blocking IGF signaling in adult neurons alleviates Alzheimer’s disease pathology through amyloid-β clearance. J Neurosci. 2015;35:11500–11513.
   PubMed Web of Science ®Google Scholar
• Verghese PB, Castellano JM, Garai K, et al. ApoE influences amyloid-β (Aβ) clearance despite minimal ApoE/Aβ association in physiological conditions. Proc Natl Acad Sci USA. 2013;110:1807–1816.
   PubMed Web of Science ®Google Scholar
• Mulder SD, Veerhuis R, Blankenstein MA, et al. The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes. Exp Neurol. 2012;233:373–379.
   PubMed Web of Science ®Google Scholar
• Kanekiyo T, Cirrito JR, Liu CC, et al. Neuronal clearance of amyloid-β by endocytic receptor. J Neurosci. 2013;33:19276–19283.
   PubMed Web of Science ®Google Scholar
• Koffie RM, Hashimoto T, Tai HC, et al. Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β. Brain. 2012;235:2155–2168.
   Web of Science ®Google Scholar
• Castellano JM, Deane R, Gottesdiener AJ, et al. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci USA. 2012;109:15502–15507.
   PubMed Web of Science ®Google Scholar
• Song Q, Huang M, Yao L, et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer’s disease by accelerating the clearance of amyloid-beta. ACS Nano. 2014;8:2345–2359.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Rajesh R. Targeted delivery of rosmarinic acid across the blood–brain barrier for neuronal rescue using polyacrylamide-chitosan-poly(lactide-co-glycolide) nanoparticles with surface cross-reacting material 197 and apolipoprotein E. Int J Pharm. 2017;528:228–241.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Liu YC. Cardiolipin-incorporated liposomes with surface CRM197 for enhancing neuronal survival against neurotoxicity. Int J Pharm. 2014;473:334–344.
   PubMed Web of Science ®Google Scholar
• Brambilla D, Verpillot R, Droumaguet BL, et al. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer’s disease. ACS Nano. 2012;6:5897–5908.
   PubMed Web of Science ®Google Scholar
• Ge JF, Qiao JP, Qi CC, et al. The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int. 2012;7:1192–1201.
   Web of Science ®Google Scholar
• Wang Y, Xia Z, Xu JR, et al. α-mangostin, a polyphenolic xanthone derivative from mangosteen, attenuates β-amyloid oligomers-induced neurotoxicity by inhibiting amyloid aggregation. Neuropharmacology. 2012;62:871–881.
   PubMed Web of Science ®Google Scholar
• Hohsfield LA, Humpel C. Intravenous infusion of monocytes isolated from 2-week-old mice enhances clearance of beta-amyloid plaques in an Alzheimer mouse model. PLOS One. 2015;10:e0121930.
   PubMed Web of Science ®Google Scholar
• Dinkins MB, Dasgupta S, Wang G, et al. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol Aging. 2014;35:1792–1800.
   PubMed Web of Science ®Google Scholar
• Xiang X, Werner G, Bohrmann B, et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med. 2016;8:992–1004.
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012;76:908–920.
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198–207.
   PubMed Web of Science ®Google Scholar
• Humpel C. Organotypic vibrosections from whole brain adult Alzheimer mice (overexpressing amyloid-precursor-protein with the Swedish-Dutch-Iowa mutations) as a model to study clearance of beta-amyloid plaques. Front Aging Neurosci. 2015;7:47.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Yan P, Ma X, et al. Enhancing Astrocytic lysosome biogenesis facilitates Aβ clearance and attenuates amyloid plaque pathogenesis. J Neurosci. 2014;34:9607–9620.
   PubMed Web of Science ®Google Scholar
• Wu J, Bei B, Yang H, et al. Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol Aging. 2013;34:791–804.
   PubMed Web of Science ®Google Scholar
• Fox BM, Beck HP, Roveto PM, et al. A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques. J Med Chem. 2015;58:5256–5273.
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Williams L, et al. Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: interim results of a randomized, double-blind, placebo-controlled, phase 1b study. Alzheimers Dement. 2015;11:P277.
   Google Scholar
• Piazza F, Winblad B. Amyloid-related imaging abnormalities (ARIA) in immunotherapy trials for Alzheimer’s disease: need for prognostic biomarkers? J Alzheimers Dis. 2016;52:417–420.
   PubMed Web of Science ®Google Scholar
• Lee LL, Ha HH, Chang YT, et al. Discovery of amyloid‐beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility. Protein Sci. 2009;18:277–286.
   PubMed Web of Science ®Google Scholar
• Villar-Pique A, Espargaro A, Sabate R, et al. Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors. Microb Cell Fact. 2012;11:55.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang X, Ladiwala ARA, et al. Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro. J Neurosci. 2013;33:19423–19433.
   PubMed Web of Science ®Google Scholar
• Gil-Bea F, Akterin S, Persson T, et al. Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer’s disease brain. EMBO Mol Med. 2012;4:1097–1111.
   PubMed Web of Science ®Google Scholar
• Churches QI, Caine J, Epa VC, et al. Naturally occurring polyphenolic inhibitors of amyloid beta aggregation. Bioorganic Med Chem Lett. 2014;24:3108–3112.
   PubMed Web of Science ®Google Scholar
• Lai AY, McLaurin J. Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochim Biophys Acta Mol Basis Dis. 2012;1822:1629–1637.
   PubMed Web of Science ®Google Scholar
• Luo Y, Vali S, Sun S, et al. Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands. ACS Chem Neurosci. 2013;4:952–962.
   PubMed Web of Science ®Google Scholar
• Mansson C, Arosio P, Hussein R, et al. Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (Aβ42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. J Biol Chem. 2014;289:31066–31076.
   PubMed Web of Science ®Google Scholar
• Yan JW, Li YP, Ye WJ, et al. Design, synthesis and evaluation of isaindigotone derivatives as dual inhibitors for acetylcholinesterase and amyloid beta aggregation. Bioorg Med Chem. 2012;20:2527–2534.
   PubMed Web of Science ®Google Scholar
• Wang SW, Wang YJ, Su YJ, et al. Rutin inhibits β-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinflammatory cytokines. Neurotoxicology. 2012;33:482–490.
   PubMed Web of Science ®Google Scholar
• Medina M, Avila J. New perspectives on the role of tau in Alzheimer’s disease. Implications for therapy. Biochem Pharmacol. 2014;88:540–547.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Harrington CR, Storey JMD. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol. 2014;88:529–539.
   PubMed Web of Science ®Google Scholar
• Chiotis K, Saint-Aubert L, Savitcheva I, et al. Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging. 2016;43:1686–1699.
   PubMed Web of Science ®Google Scholar
• Pooler AM, Noble W, Hanger DP. A role for tau at the synapse in Alzheimer’s disease pathogenesis. Neuropharmacology. 2014;76:1–8.
   PubMed Web of Science ®Google Scholar
• Wu JW, Hussaini SA, Bastille IM, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19:1085–1092.
   PubMed Web of Science ®Google Scholar
• Mondragon-Rodriguez S, Perry G, Luna-Munoz J, et al. Phosphorylation of tau protein at sites Ser396–404 is one of the earliest events in Alzheimer’s disease and down syndrome. Neuropathol Appl Neurobiol. 2014;40:121–135.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Toledo JB, Lee EB, et al. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies. Acta Neuropathol. 2014;128:679–689.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Song M, Liu X, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med. 2014;20:1254–1262.
   PubMed Web of Science ®Google Scholar
• Glodzik L, Rusinek H, Pirraglia E, et al. Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol Aging. 2014;35:64–71.
   PubMed Web of Science ®Google Scholar
• Qiu L, Ng G, Tan EK, et al. Chronic cerebral hypoperfusion enhances tau hyperphosphorylation and reduces autophagy in Alzheimer’s disease mice. Sci Rep. 2016;6:23964.
   PubMed Web of Science ®Google Scholar
• Spilsbury A, Miwa S, Attems J, et al. The role of telomerase protein TERT in Alzheimer’s disease and in tau-related pathology in vitro. J Neurosci. 2015;35:1659–1674.
   PubMed Web of Science ®Google Scholar
• Domise M, Didier S, Marinangeli C, et al. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep. 2016;6:26758.
   PubMed Web of Science ®Google Scholar
• Tian M, Zhu D, Xie W, et al. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett. 2012;586:3737–3745.
   PubMed Web of Science ®Google Scholar
• Gassowska M, Czapski GA, Pająk B, et al. Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent tau phosphorylation in PC12 cells. PLOS One. 2014;9:e94259.
   PubMed Web of Science ®Google Scholar
• Rueli RH, Torres DJ, Dewing AS, et al. Selenoprotein S reduces endoplasmic reticulum stress-induced phosphorylation of tau: potential role in selenate mitigation of tau pathology. J Alzheimers Dis. 2017;55:749–762.
   PubMed Web of Science ®Google Scholar
• Platt TL, Beckett TL, Kohler K, et al. Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease. Neuroscience. 2016;315:162–174.
   PubMed Web of Science ®Google Scholar
• Vasconcelos B, Stancu IC, Buist A, et al. Heterotypic seeding of tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of tau-pathology in vivo. Acta Neuropathol. 2016;131:549–569.
   PubMed Web of Science ®Google Scholar
• Liu S, Breitbart A, Sun Y, et al. Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer’s disease related amyloid β and tau pathology. J Neurochem. 2014;128:577–591.
   PubMed Web of Science ®Google Scholar
• Salta E, Sierksma A, Eynden EV, et al. miR‐132 loss de‐represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer’s brain. EMBO Mol Med. 2016;8:987–1113.
   PubMed Web of Science ®Google Scholar
• Chen LM, Xiong YS, Kong FL, et al. Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. J Neurochem. 2012;120:157–164.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen B, Xu WF, et al. Effects of PTEN inhibition on regulation of tau phosphorylation in an okadaic acid-induced neurodegeneration model. Int J Dev Neurosci. 2012;30:411–419.
   PubMed Web of Science ®Google Scholar
• Fu H, Chen H, Wang C, et al. Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3β signaling and mitochondrial permeability transition. Mol Med. 2012;18:1128–1135.
   PubMed Web of Science ®Google Scholar
• Wu J, Li J, Hu H, et al. Rho-Kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell Mol Neurobiol. 2012;32:1187–1197.
   PubMed Web of Science ®Google Scholar
• Modi KK, Jana A, Ghosh S, et al. A physically-modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer’s disease. PLOS One. 2014;12:e0180602.
   Google Scholar
• Chen S, An FM, Yin L, et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience. 2014;256:137–146.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang ZF, Holscher C, et al. (Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol. 2012;674:280–286.
   PubMed Web of Science ®Google Scholar
• Ali T, Yoon GH, Shah SA, et al. Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus. Sci Rep. 2015;5:11708.
   PubMed Web of Science ®Google Scholar
• Gu MY, Kim J, Yang HO. The neuroprotective effects of justicidin A on amyloid beta25–35-induced neuronal cell death through inhibition and induction of autophagy in SH-SY5Y cells. Neurochem Res. 2016;41:1458–1467.
   PubMed Web of Science ®Google Scholar
• van der Harg JM, Nolle A, Zwart R, et al. The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. Cell Death Dis. 2014;5:e1393.
   PubMed Web of Science ®Google Scholar
• Radford H, Moreno JA, Verity N, et al. PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. Acta Neuropathol. 2015;130:633–642.
   PubMed Web of Science ®Google Scholar
• Absalon S, Kochanek DM, Raghavan V, et al. MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013;33:14645–14659.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Magri A, Medina DX, et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer’s disease and other tauopathies. Aging Cell. 2013;12:370–380.
   PubMed Web of Science ®Google Scholar
• Kandimalla R, Manczak M, Fry D, et al. Reduced dynamin-related protein 1 protects against phosphorylated tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Gen. 2016;25:4881–4897.
   PubMed Web of Science ®Google Scholar
• Yang CC, Kuai XX, Li YL, et al. Cornel iridoid glycoside attenuates tau hyperphosphorylation by inhibition of PP2A demethylation. J Evid Based Complementary Altern Med 2013;2013: Article ID 108486.
   Google Scholar
• Laurent C, Eddarkaoui S, Derisbourg M, et al. Beneficial effects of caffeine in a transgenic model of Alzheimer’s disease-like tau pathology. Neurobiol Aging. 2014;35:2079–2090.
   PubMed Web of Science ®Google Scholar
• Yang S, Gong Q, Wu Q, et al. Alkaloids enriched extract from Dendrobium nobile Lindl. attenuates tau protein hyperphosphorylation and apoptosis induced by lipopolysaccharide in rat brain. Phytomedicine. 2014;21:712–716.
   PubMed Web of Science ®Google Scholar
• Chen J, Deng X, Liu N, et al. Quercetin attenuates tau hyperphosphorylation and improves cognitive disorder via suppression of ER stress in a manner dependent on AMPK pathway. J Funct Foods. 2016;22:463–476.
   Web of Science ®Google Scholar
• Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimers Dis. 2015;44:705–720.
   PubMed Web of Science ®Google Scholar
• Akoury E, Pickhardt M, Gajda M, et al. Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew Chem Int Ed Engl. 2013;52:3511–3515.
   PubMed Web of Science ®Google Scholar
• Baddeley TC, McCaffrey J, Storey JMD, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer’s disease. J Pharmacol Exp Ther. 2015;352:110–118.
   PubMed Web of Science ®Google Scholar
• Graham DL, Gray AJ, Joyce JA, et al. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology. 2014;79:307–313.
   PubMed Web of Science ®Google Scholar
• Cook C, Carlomagno Y, Gendron TF, et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Gen. 2014;23:104–116.
   PubMed Web of Science ®Google Scholar
• Wobst HJ, Sharma A, Diamond MI, et al. The green tea polyphenol (–)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 2015;589:77–83.
   PubMed Web of Science ®Google Scholar
• Mohamed T, Hoang T, Jelokhani-Niaraki M, et al. Tau-derived-hexapeptide 306VQIVYK311 aggregation inhibitors: nitrocatechol moiety as a pharmacophore in drug design. ACS Chem Neurosci. 2013;4:1559–1570.
   PubMed Web of Science ®Google Scholar
• Wang CK, Northfield SE, Huang YH, et al. Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold. Eur J Med Chem. 2016;109:342–349.
   PubMed Web of Science ®Google Scholar
• McEwan WA, Falcon B, Vaysburd M, et al. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci USA. 2017;114:574–579.
   PubMed Web of Science ®Google Scholar
• Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584–1593.
   PubMed Web of Science ®Google Scholar
• Rao MV, McBrayer MK, Campbell J, et al. Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci. 2014;4:9222–9234.
   Web of Science ®Google Scholar
• McCormick AV, Wheeler JM, Guthrie CR, et al. Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry. 2013;73:464–471.
   PubMed Web of Science ®Google Scholar
• Han DH, Na HK, Choi WH, et al. Direct cellular delivery of human proteasomes to delay tau aggregation. Nat Commun. 2014;5:5633.
   PubMed Web of Science ®Google Scholar
• Ballatore C, Crowe A, Piscitelli F, et al. Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure–activity relationship leads to selection of candidates with desirable in vivo properties. Bioorg Med Chem. 2012;20:4451–4461.
   PubMed Web of Science ®Google Scholar
• Okuda M, Hijikuro I, Fujita Y, et al. PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo. PLOS One. 2015;10:e0117511.
   PubMed Web of Science ®Google Scholar
• Santa-Maria I, Diaz-Ruiz C, Ksiezak-Reding H, et al. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy. Neurobiol Aging. 2012;33:2072–2081.
   PubMed Web of Science ®Google Scholar
• Haque MM, Kim D, Yu YH, et al. Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking. Amyloid. 2014;21:185–190.
   PubMed Web of Science ®Google Scholar
• Paranjape SR, Chiang YM, Sanchez JF, et al. Inhibition of tau aggregation by three aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde. Planta Med. 2014;80:77–85.
   PubMed Web of Science ®Google Scholar
• Yao J, Gao X, Sun W, et al. Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid. Biochemistry. 2013;52:1893–1902.
   PubMed Web of Science ®Google Scholar
• Okuda M, Hijikuro I, Fujita Y, et al. Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors. Bioorg Med Chem Lett. 2016;26:5024–5028.
   PubMed Web of Science ®Google Scholar
• Frenkel-Pinter M, Tal S, Scherzer-Attali R, et al. Cl-NQTrp alleviates tauopathy symptoms in a model organism through the inhibition of tau aggregation-engendered toxicity. Neurodegener Dis. 2017;17:73–82.
   PubMed Web of Science ®Google Scholar
• Polito VA, Li H, Martini‐Stoica H, et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. EMBO Mol Med. 2014;6:1105–1114.
   PubMed Web of Science ®Google Scholar
• Polydoro M, de Calignon A, Suarez-Calvet M, et al. Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer’s disease. J Neurosci. 2013;33:13300–13311.
   PubMed Web of Science ®Google Scholar
• Tennstaedt A, Popsel S, Truebestein L, et al. Human high temperature requirement serine protease a1 (HTRA1) degrades tau protein aggregates. J Biol Chem. 2012;287:20931–20941.
   PubMed Web of Science ®Google Scholar
• Walls KC, Ager RR, Vasilevko V, et al. p-tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett. 2014;575:96–100.
   PubMed Web of Science ®Google Scholar
• Yanamandra K, Jiang H, Mahan TE, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2:278–288.
   PubMed Web of Science ®Google Scholar
• Congdon EE, Gu J, Sait HBR, et al. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288:35452–35465.
   PubMed Web of Science ®Google Scholar
• Esteves-Villanueva JO, Trzeciakiewicz H, Loeffler DA, et al. Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation. Biochemistry. 2015;54:293–302.
   PubMed Web of Science ®Google Scholar
• Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18:794–799.
   PubMed Web of Science ®Google Scholar
• Dorszewska J, Prendecki M, Oczkowska A, et al. Molecular basis of familial and sporadic Alzheimer’s Disease. Curr Alzheimer Res. 2016;13:952–963.
   PubMed Web of Science ®Google Scholar
• Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 1996;55:1023–1025.
   PubMed Web of Science ®Google Scholar
• Neve RL, Robakis NK. Alzheimer’s disease: a re-examination of the amyloid hypothesis. Trends Neurosci. 1998;21:15–19.
   PubMed Web of Science ®Google Scholar
• Wes PD, Sayed FA, Bard F, et al. Targeting microglia for the treatment of Alzheimer’s disease. Glia. 2016;64:1710–1732.
   PubMed Web of Science ®Google Scholar
• Itzhaki RF. Herpes simplex virus type 1 and Alzheimer’s disease: increasing evidence for a major role of the virus. Front Aging Neurosci. 2014;11:1–9.
   Google Scholar
• Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaque. J Pathol. 2009;217:131–138.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.
   PubMed Web of Science ®Google Scholar
• Wozniak MA, Frost AL, Preston CM, et al. Antivirals reduce the formation of key Alzheimer’s disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One. 2011;6:e25152.
   PubMed Web of Science ®Google Scholar
• Cunnane SC, Courchesne‐Loyer A, St-Pierre V, et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann NY Acad Sci. 2016;1367:12–20.
   PubMed Web of Science ®Google Scholar
• Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:1–10.
   PubMed Web of Science ®Google Scholar
• Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. Neurosci Res. 2003;72:603–612.
   Web of Science ®Google Scholar
• McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s disease. Eur J Pharmacol. 2010;630:158–162.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang Y, Yuan G, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. J Investig Med. 2015;63:267–272.
   PubMed Web of Science ®Google Scholar
• Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
   PubMed Web of Science ®Google Scholar
• Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 2014;221:T31–T41.
   PubMed Web of Science ®Google Scholar
• Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement. 2014;10:S12–S25.
   PubMed Web of Science ®Google Scholar
• Klinge PM, Harmening K, Miller MC, et al. Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer’s disease. Neurosci Lett. 2011;497:6–10.
   PubMed Web of Science ®Google Scholar
• Heile A. Clinical transplantation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal stem cell biodelivery of glucagon-like peptide-1. Dialogues Clin Neurosci. 2011;13:279–286.
   PubMedGoogle Scholar
• Chen Y, Zhang J, Zhang B, et al. Targeting insulin signaling for the treatment of Alzheimer’s disease. Curr Top Med Chem. 2016;16:485–492.
   PubMed Web of Science ®Google Scholar
• Kosaraju J, Gali CC, Khatwal RB, et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer’s disease. Neuropharmacology. 2013;72:291–300.
   PubMed Web of Science ®Google Scholar
• Kosaraju J, Madhunapantula SRV, Chinni S, et al. Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer’s disease. Behav Brain Res. 2014;267:55–65.
   PubMed Web of Science ®Google Scholar
• Gault VA, Lennox R, Flatt PR. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab. 2015;17:403–413.
   PubMed Web of Science ®Google Scholar
• Yang D, Nakajo Y, Iihara K, et al. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res. 2013;1517:104–113.
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol. 2004;6:589–596.
   Web of Science ®Google Scholar
• Matteucci E, Giampietro O. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors. Curr Med Chem. 2015;22:1573–1581.
   PubMed Web of Science ®Google Scholar
• Mander BA, Winer JR, Jagust WJ, et al. Sleep: a novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer’s disease? Trends Neurosci. 2016;39:552–566.
   PubMed Web of Science ®Google Scholar
• Longo FM, Massa SM. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12:507–525.
   PubMed Web of Science ®Google Scholar
• Song JH, Yu JT, Tan L. Brain-derived neurotrophic factor in Alzheimer’s disease: risk, mechanisms, and therapy. Mol Neurobiol. 2015;52:1477–1493.
   PubMed Web of Science ®Google Scholar
• Budni J, Bellettini-Santos T, Mina F, et al. The involvement of BDNF, NGF and GDNF in aging and Alzheimer’s disease. Aging Dis. 2015;6:331–341.
   PubMed Web of Science ®Google Scholar
• Honea RA, Cruchaga C, Perea RD, et al. Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer’s disease neurodegeneration. PLoS ONE. 2013;8:e76001.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lian Y, Chen Y, et al. Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer’s disease induced by Aβ1–42. PLoS ONE. 2015;10:e0122415.
   PubMed Web of Science ®Google Scholar
• Jiao SS, Shen LL, Zhu C, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Transl Psychiatry. 2016;6:e907.
   PubMed Web of Science ®Google Scholar
• Prior M, Dargusch R, Ehren JL, et al. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther. 2013;5:25.
   PubMed Web of Science ®Google Scholar
• Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2014;17:110–130.
   Web of Science ®Google Scholar
• Coelho FG, Vital TM, Stein AM, et al. Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer’s disease. J Alzheimers Dis. 2014;39:401–408.
   PubMed Web of Science ®Google Scholar
• Angelova A, Angelov B, Drechsler M, et al. Neurotrophin delivery using nanotechnology. Drug Discov Today. 2013;18:1263–1271.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chen CL, Rajesh R. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration. Acta Biomater. 2019;87:207–222.
   PubMed Web of Science ®Google Scholar